Search results
Showing 501 to 550 of 8903 results
Involving you in the development of NICE guidance.
Our board has 2 sub-committees: the audit and risk assurance committee and the remuneration committee.
We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.
We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
Home What NICE does Life sciences: how to get your product to market NICE Advice service {"@context":"http://schema.org","@type":"BreadcrumbList"
If you’re unsure where to start or your circumstances are unique, we encourage you to get in touch. We’ll work with you to unpick your challenges and find a solution that meets your needs.
Home Get involved Our committees...
Home Get involved Our committees...
To contact us, NICE's website is usually the quickest way to find the answer to a query.
NICE's Freedom of Information Act 2000 provides a right of access to recorded information held by public authorities.
How NICE uses cookies and how you can manage them.
Supporting the health and care system to implement virtual wards
Virtual wards (also known as hospital at home) provide hospital level care at home.
Referral points to virtual wards are similar to traditional models of care. Our guidance and advice can help you decide where to provide care and what to consider.
Each year we work with NHSE and the DHSC to prioritise topics for development.
Using our content internationally. Includes information on fees and licensing agreements for both AI and non AI requests.
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Mental health services {"@context":"http://schema.org"
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Mental health services {"@context":"http://schema.org"
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Families and relationships settings...
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Families and relationships settings...
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Families and relationships settings...
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Services for older people {"@context":"http://schema.org"
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Learning disability settings {"@context":"http://schema
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Learning disability settings {"@context":"http://schema
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Learning disability settings {"@context":"http://schema
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Mental health services {"@context":"http://schema.org"
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers {"@context":"http://schema
Home Implementing NICE guidance Social care...
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios {"@context":"http://schema.org","@type":"BreadcrumbList"
NICE is unable to make a recommendation on adagrasib (Krazati) for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer in adults. This is because Bristol Myers Squibb will consider restarting this evaluation when the final overall survival analysis can be included in the economic model.
Show all sections
Sections for TA1076
Evidence-based recommendations on dapagliflozin for treating chronic kidney disease in adults.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios {"@context":"http://schema.org","@type":"BreadcrumbList"
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Services for older people {"@context":"http://schema.org"
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios {"@context":"http://schema.org","@type":"BreadcrumbList"
Find individual child abuse and neglect recommendations quickly and links to full guideline.
Home Implementing NICE guidance...
Support for delivering quality, safety and efficiency in the optimisation of medicines.
We support the wellbeing of our staff in a number of ways including an employee assistance programme, mental health first aiders and a variety of health and wellbeing activities.
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) (TA1078)
NICE is unable to make a recommendation on fosdenopterin (Nulibry) for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the appraisal.
Show all sections
Sections for TA1078
Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.
Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)
Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.
View recommendations for HTG752Show all sections
We work with the clinical classifications service of NHS Digital to provide relevant clinical coding information for interventional procedure and medical technologies guidance.
The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.